Noesion Radarnoesion.ai
Market2026-10-26

Pathos AI launched multi-year collaborations with Bristol Myers Squibb and Tempus AI. They will build a curated dataset and agentic AI capabilities for Alzheimer’s disease. Bristol Myers Squibb is leading Pathos AI’s $237 million Series E round. The round values Pathos AI at approximately $3 billion post-money. BMS gains three-year exclusive rights to apply Pathos’ Foundry platform across its neuroscience portfolio.

What changed

Pathos AI had no multi-year collaborations with Bristol Myers Squibb or Tempus AI for Alzheimer’s drug development.

What it unlocks

Building a curated dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions.

  • $237 million Series E round
  • $3 billion post-money valuation
  • 3-year exclusive rights
  • 190 patients treated in Phase I

What you need to act on it

  • multi-year strategic collaborations
  • BMS leading Series E round

Sources

Send this to someone who needs it

Shares the story and its sources. Nothing about you.

What does this mean for your job?

This is the story as everyone gets it. Once a week we send you the version written for your role — what changed, why it matters for the work you actually do, and one thing to try. Free while we tune it.